EBS — Emergent BioSolutions Share News
0.000.00%
Last trade - 00:00- $639.03m
- $1.08bn
- $742.90m
Ex-CEO sued by New York for insider trading tied to COVID-19 vaccine contamination
Brief: Emergent Biosolutions Receives U.S. FDA Approval On Supplemental New Drug Application For Narcan® Nasal Spray To Be Packaged In A New Carrying Case, Making Life-Saving Naloxone More Accessible For Everyday Preparedness
Brief: Emergent Biosolutions Announces $100 Million Paydown Of Term Loan Principal, A Significant Step Achieved Toward Its Multi-Year Transformation
Brief: Emergent Bio- Receives $21.5 Mln Order From U.S. Department Of War To Supply Biothrax In 2026
Brief: Emergent Biosolutions And Panther Announce Agreement To Support The Continuation Of The Africa CDC-Led Mpox Study In Africa
Brief: Emergent Biosolutions Marks 10-Year Anniversary Of The U.S. FDA Approval Of Narcan® Nasal Spray And Reinforces Its Commitment To Increasing Naloxone Access
Emergent BioSolutions Q3 revenue beats guidance, raises full-year outlook
Brief: Emergent Biosolutions Secures $29 Million In MCM Product Orders From International Government Partner
Brief: Emergent BioSolutions Secures $17M Contract Update For TEMBEXA To Strengthen U.S. Smallpox Antiviral Supply Chain
Brief: Emergent Gets U.S. Contract Update for ACAM2000® Smallpox & Mpox Vaccine
Emergent BioSolutions Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Emergent BioSolutions Q2 Revenue USD 140.9 Million
Emergent BioSolutions Inc expected to post a loss of 49 cents a share - Earnings Preview
Brief: New Publication In Expert Review Of Anti-Infective Therapy Evaluates Brincidofovir As Potential Antiviral Treatment For Mpox
Brief: Emergent Biosolutions Secures $62.4 Million Contract Modification
Comment: USD/JPY rally capped again by daily Ichimoku cloud?
U.S. STOCKS ON THE MOVE-Netflix, Acadia Pharma, CoreWeave
Emergent BioSolutions Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Emergent BioSolutions Q1 Revenue USD 222.2 Million